RBC Capital Maintains Outperform on Chemed, Lowers Price Target to $697
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix maintains an Outperform rating on Chemed (NYSE:CHE) but lowers the price target from $712 to $697.
May 21, 2024 | 2:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital's analyst Ben Hendrix maintains an Outperform rating on Chemed but lowers the price target from $712 to $697. This suggests continued confidence in the company's performance, albeit with slightly tempered expectations.
The maintained Outperform rating indicates continued positive sentiment towards Chemed's performance. However, the lowered price target suggests a slight reduction in expected upside, which may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100